Stock KV PHARMACEUTICAL CO
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases KV Pharmaceutical Co

Equities

US4827402060

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for KV Pharmaceutical Co
2012 K-V Pharmaceutical Company : K-V Pharmaceutical files for bankruptcy protection RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
KV Pharmaceutical Co : Ther-Rx Corporation and Perrigo Company Announce the Availability of Gynazole-1® (Butoconazole Nitrate Vaginal Cream USP, 2%) for Prescribing
PU
KV Pharmaceutical Co : K-V Pharmaceutical Receives Court Approval of Hologic Settlement
PU
KV Pharmaceutical Co : K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
PU
K-V Pharmaceutical Company : K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
PU
K-V Pharmaceutical Company : K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
PR
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Planned Transition of Trading of Class A and Class B Common Shares to the OTC Markets
PU
K-V Pharmaceutical Company : Files Voluntary Petitions for Reorganization to Restructure Financial Obligations
PU
K-V Pharmaceutical Company : Announces Additional Notification from NYSE Regarding Listing Criteria
PR
K-V Pharmaceutical Company : Announces Notification from NYSE Regarding Listing Criteria
PR
K-V Pharmaceutical Company : to Present at Imperial Capital 2012 Healthcare Investor Forum
PR
K-V Pharmaceutical Company : to Present at Needham & Company 11th Annual Healthcare Conference
PR
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call
PR
K-V Pharmaceutical Company : Comments on Recent Settlement with the Department of Justice
PU
K-V Pharmaceutical Company : Independent Laboratory Testing Demonstrates Important Quality Differences Between FDA-Approved Makena® and Compounded 17P Formulations
PU
K-V Pharmaceutical Company : K-V Pharmaceutical Announces Updated Makena® Performance Metrics
PR
KV PHARMA'A' : K-V PHARMACEUTICAL COMMENTS ON ACOG AND SMFM INFORMATION UPDATE REGARDING 17-ALPHA HYDROXYPROGESTERONE CAPROATE – FDA-APPROVED MAKENA™ AND COMPOUNDED 17P
PU
KV PHARMA'A' : K-V Pharmaceutical Company to Present at Imperial Capital's 5th Annual Global Opportunities Conference
PR
KV PHARMA'A' : K-V PHARMACEUTICAL COMPANY ANNOUNCES THE COMPLETION OF THE SALE OF NESHER PHARMACEUTICALS, INC. ITS GENERIC PHARMACEUTICAL BUSINESS
PU
KV PHARMA'A' : K-V Pharmaceutical Company Announces Filing of First Quarter Fiscal 2012 Form 10-Q and Schedules Investor Conference Call
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News KV Pharmaceutical Co
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW